SEARCH FOR MARKERS OF EFFICIENCY OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
- 作者: Gutorov S.L.1, Borisova E.I.1, Chichikov E.I.1, Denisenko A.N.1, Borisova Y.I1, Chichikov Y.I1, Denisenko AL1, Gutorov SL1
-
隶属关系:
- 期: 编号 17 (2011)
- 页面: 44-46
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279050
- ID: 279050
如何引用文章
全文:
详细
作者简介
Sergey Gutorov
Elena Borisova
Evgeniy Chichikov
Arkadiy Denisenko
Ye Borisova
Ye Chichikov
A Denisenko
S Gutorov
参考
- Gerger A, Zhang W, Yang D, et al. Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy. Proc Am Soc Clin Oncol 2011 [abstr 3592].
- Hansen T, Christensen RD, Andersen RF, et al. The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study. Proc Am Soc Clin Oncol 2011 [abstr 3600].
- Weickhardt J, Williams D, Lee C, et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. Proc Am Soc Clin Oncol 2011 [abstr 3531].
- Guchelaar H, Pander J, Bohringer S, et al. Genome-wide association study (GWAS) of the efficacy of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer in the CAIRO2 trial of the Dutch Colorectal Cancer Group (DCCG). Proc Am Soc Clin Oncol 2011 [abstr 3609].
- George TJ, Liu H, Duckworth LV, et al. Determination of genomic profile to predict clinical response to FOLFOX plus bevacizumab in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2011 [abstr 3598].
补充文件
![](/img/style/loading.gif)